• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PARP抑制剂用于患有卵巢癌和乳腺癌的BRCA1/BRCA2种系突变携带者。

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.

作者信息

Annunziata Christina M, Bates Susan E

机构信息

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute 10 Center Drive - Room 12N226, Bethesda, MD 20892-1906 USA.

出版信息

F1000 Biol Rep. 2010 Feb 11;2:10. doi: 10.3410/B2-10.

DOI:10.3410/B2-10
PMID:20948822
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2948351/
Abstract

BRCA and poly-ADP ribose polymerase (PARP) regulate pathways of DNA repair. Due to the accumulation of mutations introduced by error-prone DNA repair, breast and ovarian cancers develop in the setting of BRCA deficiency. A series of recent clinical trials has tested the use of PARP inhibition as a therapeutic strategy to target BRCA-deficient tumors.

摘要

BRCA（乳腺癌易感基因）和聚ADP核糖聚合酶（PARP）调节DNA修复途径。由于易出错的DNA修复所引入的突变积累，在BRCA缺陷的情况下会发生乳腺癌和卵巢癌。最近的一系列临床试验测试了使用PARP抑制作为靶向BRCA缺陷肿瘤的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/2948351/33fadaad4fcd/1757-594X-0002-0000000010-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/2948351/33fadaad4fcd/1757-594X-0002-0000000010-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/2948351/33fadaad4fcd/1757-594X-0002-0000000010-g001.jpg

相似文献

1
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.PARP抑制剂用于患有卵巢癌和乳腺癌的BRCA1/BRCA2种系突变携带者。
F1000 Biol Rep. 2010 Feb 11;2:10. doi: 10.3410/B2-10.
2
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].[从聚（ADP - 核糖）的发现到PARP抑制剂在癌症治疗中的应用]
Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15.
3
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.聚（ADP - 核糖）聚合酶抑制剂在高级别浆液性卵巢癌中的临床应用
Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28.
4
Advances in PARP inhibitors for the treatment of breast cancer.用于治疗乳腺癌的PARP抑制剂的进展
Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20.
5
The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.聚（ADP-核糖）聚合酶（PARP-1）抑制剂对乳腺癌的抑制和治疗。
Int J Biol Sci. 2006;2(4):179-85. doi: 10.7150/ijbs.2.179. Epub 2006 Jun 10.
6
Homologous recombination deficiency and ovarian cancer.同源重组缺陷与卵巢癌
Eur J Cancer. 2016 Jun;60:49-58. doi: 10.1016/j.ejca.2016.03.005. Epub 2016 Apr 9.
7
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.妇科癌症中的新型靶向药物：合成致死、同源重组缺陷与PARP抑制剂
Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9.
8
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.PARP 抑制剂在乳腺癌中的应用：将合成致死性带入临床实践。
Cancer. 2018 Jun 15;124(12):2498-2506. doi: 10.1002/cncr.31307. Epub 2018 Apr 16.
9
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.BRCA 基因突变与三阴性乳腺癌中的聚（ADP-核糖）聚合酶抑制剂。
Adv Exp Med Biol. 2017;1026:271-286. doi: 10.1007/978-981-10-6020-5_13.
10
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.多聚（ADP-核糖）聚合酶抑制剂在三阴性乳腺癌中的应用。
Cancer J. 2010 Jan-Feb;16(1):48-52. doi: 10.1097/PPO.0b013e3181cf01eb.

引用本文的文献

1
Targeting the Sodium-Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia.靶向钠钾泵作为急性髓系白血病的治疗策略。
Cancer Res. 2024 Oct 15;84(20):3354-3370. doi: 10.1158/0008-5472.CAN-23-3560.
2
Inhibition of APE1 Expression Enhances the Antitumor Activity of Olaparib in Triple-Negative Breast Cancer.抑制APE1表达可增强奥拉帕尼在三阴性乳腺癌中的抗肿瘤活性。
Evid Based Complement Alternat Med. 2022 Apr 13;2022:6048017. doi: 10.1155/2022/6048017. eCollection 2022.
3
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.

本文引用的文献

1
DNA damage, aging, and cancer.DNA损伤、衰老与癌症。
N Engl J Med. 2009 Oct 8;361(15):1475-85. doi: 10.1056/NEJMra0804615.
2
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.异常管腔祖细胞作为BRCA1突变携带者基底肿瘤发生的候选靶细胞群。
Nat Med. 2009 Aug;15(8):907-13. doi: 10.1038/nm.2000. Epub 2009 Aug 2.
3
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.对携带BRCA突变的肿瘤中聚（ADP - 核糖）聚合酶的抑制作用。
MammaPrint 和 Blueprint 全面捕捉早期乳腺癌患者的癌症特征。
Genes Chromosomes Cancer. 2022 Mar;61(3):148-160. doi: 10.1002/gcc.23014. Epub 2021 Dec 11.
4
The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.新型聚（ADP - 核糖）抑制剂在治疗具有遗传性种系BRCA1/2突变的局部晚期和转移性Her-2/neu阴性乳腺癌中的作用。文献综述
J Med Life. 2021 Jan-Mar;14(1):17-20. doi: 10.25122/jml-2020-0132.
5
Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy.拉美乳腺癌中 DNA 修复基因种系突变的全景：PARP 抑制剂和免疫疗法的机会。
Genes (Basel). 2019 Oct 10;10(10):786. doi: 10.3390/genes10100786.
6
Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.类钙调蛋白3是以单核苷酸多态性、雌激素和选择性雌激素受体调节剂依赖的方式作为雌激素受体α基因表达和药物反应的共调节因子。
Breast Cancer Res. 2017 Aug 18;19(1):95. doi: 10.1186/s13058-017-0890-x.
7
Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.男性乳腺癌的生存结果比女性差可能归因于肿瘤亚型。
Oncotarget. 2016 Dec 27;7(52):87532-87542. doi: 10.18632/oncotarget.12052.
8
BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.乳腺癌耐药蛋白（BCRP）和P-糖蛋白（P-gp）在三阴性基底样乳腺癌细胞系中的接力过表达：对奥拉帕尼耐药的潜在作用
Sci Rep. 2015 Aug 3;5:12670. doi: 10.1038/srep12670.
9
The role of Kif4A in doxorubicin-induced apoptosis in breast cancer cells.Kif4A在阿霉素诱导的乳腺癌细胞凋亡中的作用。
Mol Cells. 2014 Nov;37(11):812-8. doi: 10.14348/molcells.2014.0210. Epub 2014 Nov 5.
10
Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues.在临床实践中运用新基因技术进行个性化医疗的翻译：伦理问题
Per Med. 2014;11(2):211-222. doi: 10.2217/pme.13.104.
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
4
Synthetic lethality--a new direction in cancer-drug development.合成致死性——癌症药物研发的新方向。
N Engl J Med. 2009 Jul 9;361(2):189-91. doi: 10.1056/NEJMe0903044. Epub 2009 Jun 24.
5
Targeted therapy for cancer using PARP inhibitors.使用聚（ADP-核糖）聚合酶（PARP）抑制剂的癌症靶向治疗
Curr Opin Pharmacol. 2008 Aug;8(4):363-9. doi: 10.1016/j.coph.2008.06.016.
6
BRCA1 regulates human mammary stem/progenitor cell fate.BRCA1基因调控人类乳腺干细胞/祖细胞的命运。
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1680-5. doi: 10.1073/pnas.0711613105. Epub 2008 Jan 29.
7
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.雌激素受体α、BRCA1和FANCF启动子甲基化出现在散发性乳腺癌的不同亚组中。
Breast Cancer Res Treat. 2008 Sep;111(1):113-20. doi: 10.1007/s10549-007-9766-6. Epub 2007 Oct 12.
8
Meta-analysis of BRCA1 and BRCA2 penetrance.BRCA1和BRCA2基因外显率的荟萃分析。
J Clin Oncol. 2007 Apr 10;25(11):1329-33. doi: 10.1200/JCO.2006.09.1066.
9
The concept of synthetic lethality in the context of anticancer therapy.抗癌治疗背景下的合成致死概念。
Nat Rev Cancer. 2005 Sep;5(9):689-98. doi: 10.1038/nrc1691.
10
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.BRCA基因在DNA修复中的作用与癌症易感性之间的关系。
Trends Mol Med. 2002 Dec;8(12):571-6. doi: 10.1016/s1471-4914(02)02434-6.